Drugs / Scipibaimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07388758 | Feb 2026 → Feb 2028 expected | nasopharyngeal carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Scipibaimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07388758 ↗ |
| Known as | CM310 | “Scipibaimab (CM310) is a humanized IgG4 monoclonal antibody that selectively binds to a unique epitope on human IL-4Rα, thereby simultaneously blocking IL-4 and IL-13 signaling...” NCT07388758 ↗ |
| Action | Inhibit | “Scipibaimab (CM310) is a humanized IgG4 monoclonal antibody that selectively binds to a unique epitope on human IL-4Rα, thereby simultaneously blocking IL-4 and IL-13 signaling” NCT07388758 ↗ |
| Modality | Monoclonal antibody | “Scipibaimab (CM310) is a humanized IgG4 monoclonal antibody” NCT07388758 ↗ |
| Route | Subcutaneous | “scipibaimab 300 mg subcutaneous” NCT07388758 ↗ |
| Target | IL4R | “Scipibaimab (CM310) is a humanized IgG4 monoclonal antibody that selectively binds to a unique epitope on human IL-4Rα” NCT07388758 ↗ |